NCT03417284View on ClinicalTrials.gov

Melphalan Hydrochloride in Treating Participants With Newly-Diagnosed Multiple Myeloma Undergoing Donor Stem Cell Transplantation

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

October 9, 2019

Primary Completion Date

July 18, 2024

Study Completion Date

July 18, 2024

Conditions
Plasma Cell Myeloma
Interventions
PROCEDURE

Autologous Hematopoietic Stem Cell Transplantation

Undergo HSCT

BIOLOGICAL

Filgrastim-sndz

Given SC

DRUG

Melphalan Hydrochloride

Given IV

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT03417284 - Melphalan Hydrochloride in Treating Participants With Newly-Diagnosed Multiple Myeloma Undergoing Donor Stem Cell Transplantation | Biotech Hunter | Biotech Hunter